The Proportion of Randomized Controlled Trials That Inform Clinical Practice: A 1 Longitudinal Cohort Study of Trials Registered on ClinicalTrials.gov 2 3 4 5 Nora Hutchinson¹ M.D., C.M., MPhil, Hannah Moyer¹ BSc, Deborah A. Zarin² MD, Jonathan Kimmelman^{1*} PhD 6 7 8 1. Studies of Translation, Ethics and Medicine (STREAM), Biomedical Ethics Unit, 9 McGill University, Montreal, Quebec 10 11 2. Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and 12 Harvard, Cambridge, Massachusetts 13 14 *Corresponding Author: 15 16 Dr. Jonathan Kimmelman School of Population and Global Health, McGill University 17 2001 McGill College Avenue, Montreal QC H3A 1G1 18 19 Canada 20 21 Telephone: 514-398-3306 22 Email: jonathan.kimmelman@mcgill.ca 23 24 Word Count: 3031 words 25 Conflicts of Interest: JK received consulting fees from Amylyx Inc. Authors declare no 26 other potential conflicts of interest. 27 28

30 Abstract

31

32 Background

- 33 Prior studies suggest that clinical trials are often hampered by problems in design,
- 34 conduct and reporting that limit their uptake in clinical practice. We have described
- 35 "informativeness" as the ability of a trial to guide clinical, policy or research decisions.
- 36 Little is known about the proportion of initiated trials that inform clinical practice.
- 37

38 <u>Methods</u>

- 39 We created a cohort of randomized interventional clinical trials in three disease areas
- 40 (ischemic heart disease, diabetes mellitus and lung cancer), that were initiated between
- 1 January 2009 and 31 December 2010 using ClinicalTrials.gov. We restricted inclusion
- 42 to trials aimed at answering a clinical question related to the treatment or prevention of
- 43 disease. Our primary outcome was the proportion of clinical trials fulfilling four
- 44 conditions of informativeness: importance of the clinical question, trial design,
- 45 feasibility, and reporting of results.
- 46

47 <u>Results</u>

- 48 Our study included 125 clinical trials. The proportion meeting four conditions for
- 49 informativeness was 26.4% (95% CI 18.9 35.0). Sixty-seven percent of participants
- 50 were enrolled in informative trials. The proportion of informative trials did not differ
- 51 significantly between our three disease areas.
- 52
- 53 <u>Conclusions</u>
- 54 Our results suggest that the majority of clinical trials designed to guide clinical practice
- 55 possess features that may compromise their ability to do so. This highlights
- 56 opportunities to improve the scientific vetting of clinical research.
- 57
- 58 <u>Funding</u>
- 59 This study was funded by the Fonds de recherche Santé Québec postdoctoral
- 60 research grant (NH). This funding body was not involved in study design, conduct or 61 reporting.
- 62
- 62 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73

75 Introduction

76 77

The ultimate goal of clinical research is to produce evidence that supports 78 79 clinical and policy decisions. Numerous analyses suggest that a substantial proportion 80 of clinical trials aimed at informing clinical practice are marred by flaws in design, execution, analysis and reporting.¹⁻⁸ The initial research response to COVID-19 81 illustrated the fact that existing oversight mechanisms fail to prevent the initiation of 82 flawed trials.⁹ While unexpected events can stymie well-conceived and implemented 83 84 studies, trials that have features rendering them unlikely to inform clinical practice may do harm by misleading potential participants of their benefits, and by diverting patient-85 participants from otherwise informative research efforts.¹⁰ 86 87 We have previously described five conditions that trials should fulfill to support clinical or policy decision-making.^{10,11} First, trials must ask an important and clinically 88 89 relevant question that is not yet resolved. Second, trials must be designed to provide a

meaningful answer to that question. Third, trials must be feasible, with achievable
enrollment goals and timely primary outcome completion. Fourth, outcomes must be
analyzed in ways that support valid interpretation. Last, trial results must be made
accessible in a timely fashion.

In what follows, we created surrogate measures for four conditions of
informativeness: trial importance, design quality, feasibility, and reporting (the fifth
condition, analytical integrity, did not lend itself to objective, dichotomous assessment,
and is not assessed below). We then evaluated the proportion of "clinically directed
randomized controlled trials" in three common disease areas meeting these four

- 99 conditions. This information can be used to help healthcare and research systems
 100 identify studies in need of further scrutiny, thereby improving the impact of their
 101 research.
 102
- Methods 103 104 105 Overview of Approach 106 107 We created a cohort of randomized, interventional clinical trials in three broad 108 109 disease areas that are representative of the clinical research enterprise and that have a 110 significant impact on patient morbidity and mortality: ischemic heart disease, diabetes 111 mellitus and lung cancer. We restricted inclusion to trials that appeared to be aimed at 112 informing clinical practice by selecting trials with a stated purpose of treatment or prevention of disease and with a primary clinical outcome or appropriate surrogate. We 113 114 established milestones that could serve as objectively verifiable surrogates for four 115 conditions of informativeness. Trials in our sample were then tracked forward to assess the proportion attaining each informativeness condition. "Informative trials" were trials 116 that fulfilled all four conditions of informativeness. 117 118
- 119
- 120 Surrogate Measures for Four Conditions of Informativeness
- 121

122 We formulated surrogate measures for each condition of informativeness.

123 Measures were chosen based on i) close correspondence with each informativeness


- 124 condition; ii) objective and reproducible dichotomous scoring; and iii) feasibility of
- assessment. The four surrogates of informativeness, described in greater detail below,

126	were as follows: trial importance (determined by citation of reported trial results in high
127	quality clinical synthesizing documents; the premise of this surrogate is that these
128	documents focus on questions of clinical importance); trial design quality (assessed
129	using a modified Cochrane risk of bias (ROB) tool which is designed to identify threats
130	to study internal validity); trial feasibility (established based on ability to achieve
131	adequate participant enrollment and timely primary outcome completion); and
132	reporting (based on accessibility of primary outcome results via deposition on
133	ClinicalTrials.gov or in journal publications).
134 135 136 137 138	Clinical Trial Sampling We identified all trials registered on ClinicalTrials.gov in our three disease areas
139	with a start date from 1 January 2009 to 31 December 2010 inclusive (eMethods 1 –
140	search criteria). Our time range provided a minimum of nine years of follow-up for
141	maturation toward trial completion and fulfillment of all four surrogates of
142	informativeness. Trials were downloaded from ClinicalTrials.gov on 15 May 2020. We
143	updated trial status and enrollment for all trials meeting our inclusion criteria on 6
144	October 2021.
145	We included randomized trials i) evaluating interventions of any type; ii) aimed at
146	the treatment or prevention of ischemic heart disease, diabetes mellitus or lung cancer;
147	iii) with at least one site in the United States (most of which will thus have a regulatory
148	requirement for results reporting); ¹² and iv) interventions that were FDA approved, that
149	advanced to FDA approval, or interventions not subject to FDA approval (e.g. cardiac
150	rehabilitation). We did not include trials that we deemed unlikely to be targeted at

151	informing clinical practice by excluding: i) studies that exclusively evaluated safety,
152	diagnostic or screening interventions; and ii) early phase trials (phase 0 or phase 1)
153	(eMethods 2 – inclusion/exclusion criteria; Figure 1 – flow diagram for trial inclusion;
154	eMethods 3 – flow diagrams by disease; eMethods 4 – assessment of regulatory
155	approval status). Phase 2 trials were included in our study as they are frequently used
156	to inform both clinical and regulatory decision-making, particularly in cancer, where
157	over one quarter of recent FDA cancer drug approvals were based on the results of
158	phase 1/2 or phase 2 clinical trials. ¹³ Trials were independently screened and assessed
159	for eligibility by two authors (NH & HM), with disagreements resolved by a third
160	reviewer (JK).
161	
162	
163	
164	
165	
166	
167	
168	
169	
170	
171	
172	
173	

174 Figure 1. Flow Diagram for Trial Inclusion

175



176 177

a) Trials overlapping more than one disease area (for example, diabetes mellitus and ischemic heart

- disease) were allocated based on the disease evaluated in the primary outcome
- b) An indeterminate trial is an ongoing trial that has not surpassed twice the planned primary outcomecompletion date
- 182 c) We used a random number generator (RAND function in Microsoft Excel) to create our 33% sample

183 Scoring Conditions of Informativeness

184 185	Two authors (NH & HM) independently scored all trials for the surrogate
186	measures of the four conditions of informativeness (eTable 1; eMethods 5).
187	Disagreements were resolved by a third reviewer (JK). Because of their logical
188	relationship among surrogate measures (e.g. citation in a high quality clinical
189	synthesizing documents cannot be assessed unless trial results are available) and
190	workflow (e.g. risk of bias information is often available in systematic reviews),
191	conditions were scored sequentially. Trials not meeting one condition were not
192	advanced for evaluation of subsequent conditions. The order of scoring was as follows:
193	i) feasibility; ii) reporting; iii) importance; and iv) design. Trials meeting all four
194	conditions were deemed informative; trials failing on any condition possessed features
195	that compromised their informativeness.
196	Our assessments of informativeness began by evaluating feasibility based on
196 197	Our assessments of informativeness began by evaluating feasibility based on timely trial completion and patient-participant recruitment success. Terminated trials
197	timely trial completion and patient-participant recruitment success. Terminated trials
197 198	timely trial completion and patient-participant recruitment success. Terminated trials were deemed infeasible if the reason for termination in the ClinicalTrials.gov
197 198 199	timely trial completion and patient-participant recruitment success. Terminated trials were deemed infeasible if the reason for termination in the ClinicalTrials.gov registration record involved accrual, feasibility, funding or another non-scientific reason
197 198 199 200	timely trial completion and patient-participant recruitment success. Terminated trials were deemed infeasible if the reason for termination in the ClinicalTrials.gov registration record involved accrual, feasibility, funding or another non-scientific reason (as opposed to termination due to accumulated scientific data suggesting early
197 198 199 200 201	timely trial completion and patient-participant recruitment success. Terminated trials were deemed infeasible if the reason for termination in the ClinicalTrials.gov registration record involved accrual, feasibility, funding or another non-scientific reason (as opposed to termination due to accumulated scientific data suggesting early efficacy, futility or toxicity) (eMethods 6 – classification of reason for termination).
197 198 199 200 201 201	timely trial completion and patient-participant recruitment success. Terminated trials were deemed infeasible if the reason for termination in the ClinicalTrials.gov registration record involved accrual, feasibility, funding or another non-scientific reason (as opposed to termination due to accumulated scientific data suggesting early efficacy, futility or toxicity) (eMethods 6 – classification of reason for termination). Completed trials were deemed to have not fulfilled feasibility if final participant
197 198 199 200 201 202 203	timely trial completion and patient-participant recruitment success. Terminated trials were deemed infeasible if the reason for termination in the ClinicalTrials.gov registration record involved accrual, feasibility, funding or another non-scientific reason (as opposed to termination due to accumulated scientific data suggesting early efficacy, futility or toxicity) (eMethods 6 – classification of reason for termination). Completed trials were deemed to have not fulfilled feasibility if final participant enrollment was less than 85% of expected enrollment as listed in the final registration

207 calculated by subtracting the intended primary completion date (as stated in the final 208 registration record prior to study start) from the trial start date, then multiplying by two. 209 We next assessed results reporting by determining whether primary outcome 210 results were publicly available. Trials were categorized as reported if they either had 211 primary outcome results available on ClinicalTrials.gov or in a publication (eMethods 7 212 - methodology for publication search). When more than one publication presented 213 primary outcome results, the earliest published report was identified and advanced to 214 the next step of assessment. ClinicalTrials.gov results reporting and publication search 215 were updated in October 2021 for those trials previously deemed to have not met the 216 criteria for reporting.

217 Importance was scored by determining whether trial results were included in a high-quality review document designed to inform medical decision-making. To credit 218 219 trials with being informative even if they produced negative results, trials were first assessed for inclusion in the results of a high-quality systematic review (SR), given that 220 SR citation practices are results neutral. We assessed for trial results citation in a 221 222 Cochrane SR, Agency for Healthcare Research and Quality (AHRQ) SR or in an SR deemed of high quality based on a modified AMSTAR score (eMethods 8 - SR search 223 224 strategy and quality assessment). Trials not cited in the results of high-quality SRs 225 were evaluated for inclusion in a high-guality CPG; remaining uncited trials were then assessed for inclusion in an UpToDate review article¹⁵ (eMethods 9 – CPG search 226 strategy, CPG quality assessment and point-of-care medical database search). Trials 227 228 cited in high-quality review documents were deemed to have fulfilled the importance

Finally, design was assessed by determining whether studies were at elevated

condition. Assessment of importance was updated in October 2021 for all trialspreviously deemed to have not met the criterion for importance.

risk of bias, using a modified Cochrane Risk of Bias (ROB) tool¹⁶ (eMethods 10). When available, ROB scores were extracted directly from high-quality SRs identified during the assessment of trial importance. When unavailable, ROB scores were independently performed by two authors (NH & HM), with disagreements resolved by a third reviewer (JK). Trials were deemed to have fulfilled the design condition of informativeness if all ROB elements were deemed to be of low risk of bias, or a majority were low risk of bias with a minority of elements deemed to be of unclear risk of bias.

239 240

242

231

241 Statistical Analysis

Our primary outcome was the proportion of trials that met all four conditions of 243 244 trial informativeness. We provided a 95% binomial confidence interval for our primary outcome. We performed a sensitivity analysis on our primary outcome excluding small, 245 246 pilot-type studies that would not have been designed to inform clinical decisionmaking. These were identified based on an anticipated participant enrollment below 247 248 the lowest guartile of target enrollment for our cohort of trials. Due to concern that 249 phase 2 trials are less likely to inform clinical practice than trials of a higher phase, we performed a second sensitivity analysis on our primary outcome excluding phase 1/2 250 251 and phase 2 trials.

As secondary outcomes, we estimated the proportion of trial participants who were enrolled in informative trials, as well as the proportion of informative trials in each

of our three disease areas. We also report the proportion of trials advancing across
each condition of informativeness. We provided 95% binomial confidence intervals for
these secondary outcomes.

We compared the proportion of informative trials between disease categories 257 258 and by trial sponsor using the Chi-square test (chisq.test function in R) and provided binomial confidence intervals for each stratum. We used the fisher.test function in R to 259 260 perform a two-sided Fisher's Exact test assessing the proportion of informative trials by type of intervention and trial phase and provided exact confidence intervals for 261 each. We calculated inter-rater agreement rates using Cohen's kappa (eTable 2). We 262 defined p < 0.05 as statistically significant. All analyses were performed using R version 263 4.0.2.¹⁷ 264

Our study was not subject to Institutional Review Board approval, as it relied on 265 266 publicly accessible data. The study protocol was prospectively registered on Open Science Framework:¹⁸ deviations and amendments to the study protocol are detailed in 267 eMethods 11. The code¹⁹ and data set¹⁸ used in this analysis are available online. This 268 269 study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines for cohort studies (eMethods 12). 270 271 272 Results 273 274

275 Over half of the 125 interventional trials in our cohort were studies of drug or 276 biologic interventions (77 trials; 61.6%). The majority were Phase 2 (24 trials, 19.2%) or

- 277 Phase 3 trials (50 trials, 40.0%). Trial status was "Completed" in 99 of 125 trials
- 278 (79.2%) and "Terminated" in 15 trials (12.0%) (Table 1).

279

280 Table 1. Characteristics of Intervention Trial Cohort

281

Category	Ischemic Heart Disease Trials N = 40	Diabetes Mellitus Trials N = 57	Lung Cancer Trials N = 28	All Trials N = 125 (%)	
Trial Phase					
2 ^a	6 (15.0)	5 (8.8)	13 (46.4)	24 (19.2)	
3 ^b	11 (27.5)	26 (45.6)	13 (46.4)	50 (40.0)	
4	10 (25.0)	9 (15.8)	0 (0.0)	19 (15.2)	
NA	13 (32.5)	17 (29.8)	2 (7.1)	32 (25.6)	
Intervention					
Drug/Biologic	19 (47.5)	34 (59.6)	24 (85.7)	77 (61.6)	
Combination ^c	7 (17.5)	0 (0.0)	1 (3.6)	8 (6.4)	
Device	4 (10.0)	4 (7.0)	0 (0.0)	8 (6.4)	
Other ^d	10 (25.0)	19 (33.3)	3 (10.7)	32 (25.6)	
Trial Status					
Completed	29 (72.5)	53 (93.0)	17 (60.7)	99 (79.2)	
Terminated	7 (17.5)	1 (1.8)	7 (25.0)	15 (12.0)	
Active, NR	0 (0.0)	1 (1.8)	4 (14.3)	5 (4.0)	
Unknown	4 (10.0)	2 (3.5)	0 (0.0)	6 (4.8)	
Outcome					
Clinical	24 (60.0)	8 (14.0)	10 (35.7)	42 (33.6)	
Surrogate	16 (40.0)	49 (86.0)	18 (64.3)	83 (66.4)	
Sponsor ^e					
Industry	18 (45.0)	27 (47.4)	13 (46.4)	58 (46.4)	
Other	22 (55.0)	30 (52.6)	15 (53.6)	67 (53.6)	

282

alncluding Phase 1/2

284 ^bIncluding Phase 2/3

²⁸⁵ ^cIncluding Drug + Device, Drug + Procedure, Behavioural + Device, Radiation Therapy + Drug

^dIncluding Behavioural Intervention, Radiation Therapy, Surgical Procedure, Cellular Intervention


287 ^eAs defined in ClinicalTrials.gov registration records

288

289

- 291 Our primary outcome, the proportion of trials that informed clinical practice, was
- 292 26.4% (95% CI 18.9 35.0) (Figure 2). As a sensitivity analysis, we re-analyzed our
- 293 primary outcome excluding the 35 trials in the lowest quartile for target enrollment. This
- resulted in a proportion of informative trials of 35.6% (95% CI 25.7 46.3). We
- 295 performed a second sensitivity analysis on our primary outcome excluding phase 1/2
- and phase 2 trials. This resulted in 30.7% (95% CI 21.9 40.7) of trials meeting 4
- 297 conditions of informativeness.
- 298


Figure 2. Flow Diagram - The Proportion of Trials Meeting Four Conditions of Informativeness



A total of 193,839 participants were enrolled in the 125 trials in our cohort, of
which 129,973 (67.1% (95% CI 66.8 – 67.3)) were enrolled in informative trials. The
proportion of ischemic heart disease trials that was informative was 27.5% (95% CI
14.6 – 43.9); the proportion for diabetes mellitus trials was 31.6% (95% CI 19.9 – 45.2),
and the proportion for lung cancer was 14.3% (95% CI 4.0 – 32.7) (Figure 3).
Proportions did not vary significantly by disease area (p value = 0.23) (Figure 4). Each
surrogate measure contributed considerably to the stepwise decline in the proportion
of informative trials (eTable 3).
Studies sponsored by industry were significantly more likely to fulfill all four
conditions of informativeness than those not sponsored by industry (50.0% vs. 6.0% , p
value < 0.001)(Figure 4). Using the two-sided Fisher's exact test, there was a non-
random association between trial phase and informativeness, and type of intervention
and informativeness (Figure 4).

Figure 3. The Cumulative Proportion of Trials Meeting Four Conditions of

335 Informativeness by Disease Area



- 4F




Figure 4. The Proportion of Informative Trials by Trial Property

- A – Proportion of Informative Trials by Phase (p-value = 5.19×10^{-5}) B – Proportion of Informative Trials by Intervention Type (p-value = 0.02) C – Proportion of Informative Trials by Disease Area (HD = Heart Disease) (p-value = 0.23)
- D – Proportion of Informative Trials by Sponsor (p-value = 8.06 x 10⁻⁸)

357 Discussion

358

This study provides the first assessment of the proportion of randomized trials fulfilling four key conditions of informativeness. In our analysis, just over one fourth of trials demonstrated adequacy for study feasibility, reporting, importance, and design. The remaining 73.6% contained a limitation in design, conduct or reporting that compromised their ability to inform clinical decision-making.

364 Certain shortcomings of clinical trials are a result of experimenting in a dynamic 365 real-world environment and cannot be entirely avoided. Clinical trials are difficult to plan, and there may be defensible reasons for falling short of some conditions. For 366 367 example, changes in medical practice may render a research question irrelevant to 368 clinical practice; an emerging viral pandemic might lead to under-recruitment. 369 However, our findings underscore the major challenges sponsors and clinical 370 investigators confront in fulfilling the scientific and ethical warrant for enrolling patientparticipants in randomized trials. The goal should be to address foreseeable limitations 371 in trial design, conduct or reporting. For example, increased oversight by research 372 373 funders, including requirements for landscape analysis of completed and ongoing clinical trials to ensure trials are addressing important questions, and the provision of 374 independent scientific review to highlight vulnerabilities in trial design,²⁰ are measures 375 376 that can be implemented to increase the likelihood that trials will be informative. Many methodological weaknesses in trial design can be corrected at minor cost.⁸ 377 378 The proportion of informative trials did not differ significantly between ischemic

heart disease, diabetes mellitus and lung cancer, indicating shared challenges in
design, implementation, and reporting. Our study also demonstrated that each

381 condition of informativeness goes unfulfilled in roughly equal proportions (eTable 2), 382 suggesting that vigilance is required throughout the life cycle of a trial. Our estimates 383 for the fraction of studies fulfilling criteria for recruitment feasibility are in line with prior studies.^{14,21-23} The fraction of trials at low risk of bias is similar to prior estimates.^{8,24,25} 384 385 Our estimate for the fraction of studies fulfilling reporting requirements (90.0%) is in line 386 with prior studies that evaluated both ClinicalTrials.gov results deposition and publication,^{26,27} both of which were deemed acceptable means of results reporting in 387 our study. To our knowledge, our study is the first to apply these conditions jointly to a 388 389 sample of trials, in addition to assessing importance via citation in clinical synthesizing documents. 390

Our results also indicate that certain types of trials may be at greater risk for having their informativeness compromised. Phase 4 trials fared worse than Phase 3 trials, with only 2 of 19 fulfilling all 4 conditions of informativeness (eTable 4). Trials sponsored by industry funders were far more likely to fulfill all four conditions than those with non-industry sponsorship (50.0% vs. 6.0%). This is in keeping with prior research demonstrating greater recruitment challenges for non-industry funded trials,¹⁴ in addition to diminished compliance with timely results reporting on

398 ClinicalTrials.gov.²⁸

These results suggest that funding bodies and academic medical centers may not provide adequate resources for fulfilling the clinical mission of the trials they support. Several recent initiatives aim at improving various aspects of informativeness, including increased consideration given to the importance and clinical relevance of the research guestion, the evidentiary basis for proposed research, study registration and

reporting, by many funders.²⁹ The implementation of new frameworks, such as
INQUIRE, developed to guide academic institutions in addressing waste in research,
including assessments of research design, feasibility, transparency, relevance, and
internal and external validity, if widely adopted, may lead to further improvements in
research quality.³⁰ The SARS-CoV-2 pandemic has highlighted both the susceptibility
of our clinical research enterprise to substandard trials, while also showing what is
possible with robust research vetting, coordination and collaboration.³¹

412 Limitations

Our study should be interpreted considering several limitations. First, our 413 414 measures for each condition of informativeness are proxies for the concepts they represent. For example, scoring trial importance required citation in a clinical 415 416 synthesizing document. This measure may have erroneously classified some 417 informative trials as at risk of being uninformative (e.g. trials that evaluate disease management in niche populations that are not addressed in practice guidelines or 418 419 systematic reviews). It may also have misclassified some trials as informative (e.g. trials addressing already resolved clinical hypotheses, which might nevertheless be cited in 420 421 systematic reviews). To the former, none of the 18 trials not fulfilling the importance 422 condition involved niche populations (eTable 5). We also acknowledge that some trials may inform clinical practice despite failing our criteria. The DAPT Study (NCT00977938) 423 was a large Phase 4 study that was deemed at high risk of bias in several high-quality 424 systematic reviews.^{32,33} However, this study has had an important impact on the clinical 425 management of antiplatelet therapy following drug-eluting stent placement.³⁴ Our 426

427 metrics are best understood as capturing factors that seriously (but not fatally) 428 compromise a trial's prospects of informing practice, and that are rectifiable. Second, 429 we applied strict inclusion/exclusion criteria when identifying out cohort of "clinically directed randomized controlled trials," thus limiting generalizability to other types of 430 431 trials, including those involving diagnostics or interventions that do not advance to FDA 432 approval. The latter would require different criteria, given their primary goal of informing 433 regulatory decision-making. Third, we used a longitudinal approach, since conditions 434 like publication or citation are only fulfilled after a study is completed. Changes in 435 research practices or policy occurring over the last decade might produce different estimates for the proportion of randomized trials that are informative. 436

437

438 **Conclusions**

Trial volunteers are generally told that their participation will advance clinical practice. However, one third (33%) of patient-participants in our study were enrolled in trials that possessed at least one feature that compromised their goal of informing clinical practice. Sponsors and investigators often face unforeseeable challenges, and trials with flaws in design and implementation occasionally uncover actionable insights. Nevertheless, research systems and oversight should address persistent barriers to fulfilling the societal mission of clinical research.

447 **Bibliography**

- 448
- 1. Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. *The Lancet.* 2014;383(9912):156-165.
- Chan A-W, Song F, Vickers A, et al. Increasing value and reducing waste:
 addressing inaccessible research. *The Lancet.* 2014;383(9913):257-266.
- 453 3. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of
 454 aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?
 455 *Clin Trials.* 2005;2(3):218-229; discussion 229-232.
- 456 4. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or 457 unusable reports of biomedical research. *The Lancet.* 2014;383(9913):267-276.
- Ioannidis JPA, Greenland S, Hlatky MA, et al. Increasing value and reducing
 waste in research design, conduct, and analysis. *The Lancet.*2014;383(9912):166-175.
- 461 6. Salman RA-S, Beller E, Kagan J, et al. Increasing value and reducing waste in
 462 biomedical research regulation and management. *The Lancet.*463 2014;383(9912):176-185.
- 464 7. Yordanov Y, Dechartres A, Atal I, et al. Avoidable waste of research related to 465 outcome planning and reporting in clinical trials. *BMC Med.* 2018;16(1):87.
- 466 8. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P.
 467 Avoidable waste of research related to inadequate methods in clinical trials.
 468 BMJ. 2015;350:h809.
- 469 9. Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. *Nat Rev*470 *Drug Discov.* 2021;20(4):254-255.
- 471 10. Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical
 472 Trials. *JAMA*. 2019;322(9):813-814.
- 473 11. London AJ, Kimmelman J. Against pandemic research exceptionalism. *Science*.
 474 2020;368(6490):476-477.
- 475 12. U.S. Public Law 110-85 (Food and Drug Administration Amendments Act of 2007), Title VIII, Section 801. (<u>https://www.govinfo.gov/content/pkg/PLAW-</u> 110publ85/pdf/PLAW-110publ85.pdf) Accessed 2020/07/24.
- Tibau A, Molto C, Ocana A, et al. Magnitude of Clinical Benefit of Cancer Drugs
 Approved by the US Food and Drug Administration. *J Natl Cancer Inst.*2018;110(5):486-492.

- 481 14. Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual
 482 and human subjects protections: an empirical analysis of recently closed trials.
 483 *Clin Trials.* 2015;12(1):77-83.
- 484 15. UpToDate. (https://www.uptodate.com/home).
- Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool
 for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
- 487 17. R Core Team. R: A language and environment for statistical computing. R
 488 Foundation for Statistical Computing, Vienna, Austria. 2013. <u>http://R-project.org</u>.
- 489 18. What Fraction of Trials Inform Clinical Practice? A Longitudinal Cohort Study of
 490 Trials Registered on ClinicalTrials.gov. DOI 10.17605/OSF.IO/3EGKU.
 491 <u>https://osf.io/3egku/</u>.
- 492 19. <u>https://codeberg.org/nhutchin/Informative_Trials</u>.
- 493 20. Bierer BE, Strauss DH, White SA, Zarin DA. Universal Funder Responsibilities
 494 That Advance Social Value. *Am J Bioeth.* 2018;18(11):30-32.
- Cheng SK, Dietrich MS, Dilts DM. Predicting accrual achievement: monitoring
 accrual milestones of NCI-CTEP-sponsored clinical trials. *Clin Cancer Res.*2011;17(7):1947-1955.
- 498 22. Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National
 499 Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
 500 *J Clin Oncol.* 2010;28(35):5197-5201.
- Walters SJ, Bonacho Dos Anjos Henriques-Cadby I, Bortolami O, et al.
 Recruitment and retention of participants in randomised controlled trials: a
 review of trials funded and published by the United Kingdom Health Technology
 Assessment Programme. *BMJ Open.* 2017;7(3):e015276.
- Ndounga Diakou LA, Ntoumi F, Ravaud P, Boutron I. Avoidable waste related to
 inadequate methods and incomplete reporting of interventions: a systematic
 review of randomized trials performed in Sub-Saharan Africa. *Trials.*2017;18(1):291.
- 509 25. Vale CL, Tierney JF, Burdett S. Can trial quality be reliably assessed from
 510 published reports of cancer trials: evaluation of risk of bias assessments in
 511 systematic reviews. *BMJ.* 2013;346:f1798.
- 512 26. Chen R, Desai NR, Ross JS, et al. Publication and reporting of clinical trial
 513 results: cross sectional analysis across academic medical centers. *BMJ*.
 514 2016;352:i637.

Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of
the FDA Amendment Act with trial registration, publication, and outcome
reporting. *Trials.* 2017;18(1):333.

- 518 28. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report
 519 clinical trial results on ClinicalTrials.gov: a cohort study. *The Lancet.*520 2020;395(10221):361-369.
- 521 29. Moher D, Glasziou P, Chalmers I, et al. Increasing value and reducing waste in 522 biomedical research: who's listening? *The Lancet.* 2016;387(10027):1573-1586.
- 30. von Niederhausern B, Guyatt GH, Briel M, Pauli-Magnus C. Academic response
 to improving value and reducing waste: A comprehensive framework for
 INcreasing QUality In patient-oriented academic clinical REsearch (INQUIRE). *PLoS Med.* 2018;15(6):e1002580.
- 527 31. Kimmel SE, Califf RM, Dean NE, Goodman SN, Ogburn EL. COVID-19 Clinical
 528 Trials: A Teachable Moment for Improving Our Research Infrastructure and
 529 Relevance. *Ann Intern Med.* 2020;173(8):652-653.
- 32. Xu Y, Shen Y, Chen D, Zhao P, Jiang J. Efficacy and Safety of Dual Antiplatelet
 Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic
 Review and Network Meta-Analysis. *J Interv Cardiol.* 2021;2021:9934535.
- S33 33. Yin SH, Xu P, Wang B, et al. Duration of dual antiplatelet therapy after
 percutaneous coronary intervention with drug-eluting stent: systematic review
 and network meta-analysis. *BMJ.* 2019;365:l2222.
- S36 34. Cutlip DE, Nicolau JC. Long-term antiplatelet therapy after coronary artery
 stenting in stable patients In: UpToDate, Dardas TF (Ed), UpToDate, Waltham,
 MA.

541 Supplementary Material

- 543 eMethods 1 ClinicalTrials.gov search criteria
- 544 eMethods 2 Trial Inclusion and Exclusion criteria
- 545 eMethods 3 Flow Diagrams for Each Disease
- 546 eMethods 4 Assessment of Regulatory Approval Status
- 547 eTable 1 Addressing 4 Conditions for Informative Clinical Trials
- 548 eMethods 5 Flow Chart of Informative Criteria Assessment
- 649 eMethods 6 Classification of Reason for Termination
- eMethods 7 Methodology for Publication Search
- eMethods 8 Systematic Review Citation Search Strategy and Quality Assessment
- 652 eMethods 9 Clinical Practice Guideline and Point-of-Care Medical Database Search
- 553 Strategies and Quality Assessment
- 554 eMethods 10 Operationalization of modified Cochrane Risk of Bias score
- eMethods 11 Deviations to the Study Protocol
- 556 eMethods 12 STROBE Checklist for Cohort Studies
- 557 eTable 2 Inter-rater Agreement Rates
- 558 eTable 3 Proportion of Trials Meeting Each Criterion for Informativeness
- 559 eTable 4 Phase 4 Trials Not Meeting 4 Informativeness Criteria
- 560 eTable 5 Trials Not Cited in Clinical Review Documents
- 561
- 562
- 563

564 eMethods 1 – ClinicalTrials.gov search criteria


- 565
- 566 1.Condition or disease search terms:
- a) ISCHEMIC HEART DISEASE: coronary artery disease OR coronary disease OR 567 coronary heart disease OR coronary occlusion OR acute coronary syndrome OR 568 myocardial ischemia OR angina pectoris OR angina, stable OR angina, unstable 569 570 OR myocardial infarction OR ischemic heart disease 571 b) LUNG CANCER: Lung cancer OR lung neoplasm OR lung carcinoma OR non-572 573 small-cell lung cancer OR non-small-cell lung carcinoma OR small cell lung cancer OR small cell lung carcinoma OR lung tumor OR lung tumour 574 575 576 c) DIABETES: diabetes mellitus OR diabetes 577 578 2. Study type: "Interventional Studies (Clinical Trials)" 579 3. Recruitment status: "Recruiting, Completed, Suspended, Terminated, Active not 580 recruiting, enrolling by invitation and unknown status" 581 582 583 4. Study start: 2009-01-01 to 2010-12-31 584 585

586 eMethods 2 – Trial Inclusion and Exclusion criteria


- 587
- 588 Inclusion criteria:
- -Primary outcome = clinical decision-related outcome: including mortality, morbidity,
- 590 quality of life, functional status, need for further interventions, or an appropriate
- 591 surrogate measures (for example, ejection fraction, Hgb A1c, or progression free
- 592 survival in ischemic heart disease, diabetes mellitus and lung cancer respectively)
- 593 -Intervention of any type (drug, device, behavioral, surgical or other) directed towards
- 594 the treatment or prevention of ischemic heart disease/lung cancer/diabetes mellitus
- 595 (and not side-effects of the disease or complications from disease treatment)
- 596 -Trials with a US site
- 597 -Randomized trials
- 598 -Multi-arm trials
- 599 -Trials of interventions subject to FDA regulations and are FDA approved prior to trial 600 start
- 601 -Trials of interventions not subject to FDA regulations
- 602 -Trials of interventions subject to FDA regulations, FDA approved post trial start, and
- have at least 5 years of follow-up since FDA approval, to allow for ample time for
- 604 results incorporation into systematic reviews/clinical practice guidelines/UpToDate
- 605
- 606 <u>Exclusion criteria:</u>
- 607 -Exclusively evaluating safety, diagnostic or screening interventions
- 608 -Exclusion of phase 0 or phase 1 trials (given these early phase trials would be unlikely
- 609 to inform clinical decision-making)
- 610 -Exclusion of extension studies with primary aim to enable continued access to drug
- 611 (and without additional post-marketing surveillance outcomes)
- 612 -Indeterminate trials, which are ongoing trials have not surpassed double the allotted
- time for primary outcome completion (as first stated in the historical clinicaltrials.gov
- 614 registration record)
- 615
- 616
- 617
- 618
- 619
- 620
- 621
- 622
- 623
- 624
- 625 626
- 627
- 627 620
- 628
- 629 630

631 eMethods 3 – Flow Diagrams for Each Disease

632 Flow Diagram for Ischemic Heart Disease Interventional Trials




a) An indeterminate trial is an ongoing trial that has not surpassed twice the planned primary outcomecompletion date



a) We used a random number generator (RAND function in Microsoft Excel) to create our 33% sample

721722 Flow Diagram for Lung Cancer Interventional Trials



765 eMethods 4 – Assessment of Regulatory Approval Status

766

767 Two authors (NH & HM) independently evaluated all eligible trials for regulatory

768 approval status using Drugs@FDA¹ for drug and biological interventions and the 510(k)

769 Premarket Notification website for devices.² Interventions were classified into one of 3

categories: i) FDA approved prior to trial start (drug, biological or device interventions

approved for any use by the time of trial start); ii) FDA approved at least 5 years ago

((drug, biological or device interventions approved for any use prior to October 31,

2016); and, iii) interventions not subject to FDA approval.


774 eTable 1 – Addressing the 4 Conditions for Informative Clinical Trials

775

Conditions for Informativeness ¹	Manner in which this is evaluated
Importance: Trial hypothesis is likely to inform an important scientific, medical or policy question	 Trials are selected for inclusion in our cohort based on their potential to inform clinical decision-making, based on presence of a primary clinical outcome or appropriate surrogate. We also assess importance by evaluating the proportion of trials that are cited in clinical review documents (systematic reviews, clinical practice guidelines or point-of-care medical database articles).
Design: Trial methods are likely to provide meaningful evidence related to study hypothesis	-We assess trials that are designed to inform clinical decision-making for evidence of low risk of bias
Feasibility: Trial is likely to be feasible	 -Feasible trials include: -Completed trials that have reached ≥ 85% planned recruitment -Terminated trials stopped for an informative reason (such as efficacy, futility or safety) -Ongoing trials that have not surpassed double their anticipated primary completion timeline
Reporting: Systems are in place to ensure timely, complete and accurate reporting	-A trial is reported if primary outcome results are made available through publication or results deposition on ClinicalTrials.gov

776 777

¹Column "Conditions for Informativeness" extracted from column1 in eTable 1³



794 eMethods 6 – Classification of Reason for Termination

795

NCT	Reason for Termination	Outcome
NCT00831441	None Provided	Advanced to next step of assessment
NCT00863512	None Provided	Advanced to next step of assessment
NCT00887315	Accrual; Loss of sponsor	Infeasible
NCT00910299	Futility	Advanced to next step of assessment
NCT00932152	Accrual	Infeasible
NCT00965055	Accrual	Infeasible
NCT01041781	DSMB Recommendation	Advanced to next step of assessment
NCT01078272	Accrual	Infeasible
NCT01246011	Accrual	Infeasible
NCT00976677	None Provided	Advanced to next step of assessment
NCT01177592	Funding	Infeasible
NCT01179308	PI closed study site	Infeasible
NCT01197963	IRB Decision	Advanced to next step of assessment
NCT01231750	Accrual	Infeasible
NCT01413750	Accrual	Infeasible

797 eMethods 7 – Methodology for Publication Search

798

799 The search for publications was independently performed by two authors (NH & HM) and included an evaluation of publication links provided on ClinicalTrials.gov, as well 800 as directed searches on Google Scholar, Scopus and Medline using a combination of 801 802 the unique trial registration number (NCT number), surname of the principal investigator, indication, intervention, phase and study design. Publication identity was 803 804 confirmed by comparing trial arms, sample size, intervention details, comparators and 805 sponsor with the registration record. A published abstract was not counted as a full publication. Publication search was repeated in October 2021 by NH & HM for those 806 trials without publications when first assessed. 807 808

810 eMethods 8 – Systematic Review Citation Search Strategy and Quality

- 811 Assessment
- 812

Assessment of citation of trial results in high quality systematic reviews (SRs) was

- independently performed by two authors (NH & HM). This first involved a search for
- sources that are well known for producing high quality SRs: Cochrane SRs on the
- 816 Cochrane Database of Systematic Reviews⁴ and Agency for Healthcare Research and
- 817 Quality (AHRQ) SRs ⁵. If trials were not included in Cochrane or AHRQ reviews,
- additional SRs for published studies were identified using the Scopus database ⁶
- citation analysis search function or via Google Scholar⁷ for unpublished studies. SRs
- 820 identified through Scopus or Google Scholar that included trial results in review results
- 821 were assessed for quality using a modified AMSTAR scoring system:
- 822
- 823 Operationalization of modified AMSTAR^{8,9} scoring system

1.	Was an "a priori" design provided?	□ Yes (1)	
	Yes – the authors stated that methods were established prior to conducting the review or provided a link to a registered protocol record	□ No (0)	
	No – the authors stated that there's no protocol available or no information is provided		
2.	Was there duplicate study selection and data extraction?	□ Yes (1)	
	Yes – at least two individuals independently performed study selection and data extraction; the method for reaching consensus in the setting of disagreement was reported	□ No (0)	
		□ Can't	
	No – only one person performed either study selection or data extraction	answer (0)	
	Can't answer – no information about independent study selection and/or data extraction was provided		
3.	Was a comprehensive literature search performed?	□ Yes (1)	
	Yes – at least two electronic sources were searched; keywords or MESH terms were provided	□ No (0)	
	No – only one database was searched; no keywords or MESH terms were provided	□ Can't answer (0)	
	Can't answer – partial or no information reported		
4.	. Was a list of studies (included and excluded) provided?	□ Yes (1)	

		Yes - a list of included and excluded studies was provided	□ No (0)
		No – a list of included and excluded studies was not provided	
5.	5.	Was the scientific quality of the included studies assessed	
		and documented with a study-specific quality score provided? Yes – risk of bias or another quality metric was used and reported	□ No (0)
	No – no risk of bias or quality metric was used Can't answer – the authors state that a quality metric was done, but do not provide additional information	□ Can't answer (0)	

824 High quality review = score of $\geq 3/5$

825

Trials were deemed to have fulfilled the importance criterion if they were cited in the

results of a Cochrane SR, an AHRQ SR, or an SR achieving a modified AMSTAR score of greater or equal to 3 out of 5.

829

Assessment of citation of trial results in SRs was repeated in October 2021 by NH &
HM for those trials without an informative citation when first assessed.

832

833

834

eMethods 9 – Clinical Practice Guideline and Point-of-Care Medical Database Search Strategies and Quality Assessment

838

839 Assessment of citation of trial results in Clinical Practice Guidelines (CPGs) was

- 840 independently performed by two authors (NH & HM). CPGs were identified via Scopus
- ⁶ citation analysis for published studies or via Google Scholar ⁷ for unpublished trials.
- 842 Quality of CPGs was assessed using a modified AGREE II scoring system:
- 843
- 844 Operationalization of modified AGREE II ¹⁰ scoring system

1.	Were systematic methods used to search for evidence and					
	criteria for selection of evidence clearly described?	□ No (0)				
	Yes – the authors described electronic databases/sources where search was performed, time periods searched, key terms used; inclusion/exclusion criteria for evidence selection were outlined					
	No – no description was available/no systematic search for evidence conducted/no criteria for selection of evidence described					
2.	Were the strengths and limitations of the body of evidence					
	clearly described?					
	Yes – description of the tools used to assess quality of evidence provided (e.g. GRADE framework) or explicit discussion of the quality of the entire group of included trials provided					
	No – no evaluation of quality					
3.	Were the methods for formulating recommendations clearly					
	described?	□ No (0)				
	Yes – description of the recommendation development process was included (e.g. voting procedures) and level of consensus reached were described					
	No – no clear description of the process involved in formulating recommendations provided					
4.	Were the guidelines externally reviewed prior to publication?					
		□ No (0)				

	Yes – guidelines were externally reviewed and reviewers were not involved in the guideline development group	□ Can't answer
	No – no external review performed or reviewers not independent of guideline information	(0)
	Can't answer – insufficient information to evaluate external review process	
5	. Were competing interests of guideline developers recorded and addressed?	□ Yes (1) □ No (0)
	Yes – a description of competing interests was provided and their potential impact on guideline development discussed; guideline developers were independent from funding body / funding body did not influence final recommendations	
	No – no competing interests described, or impact on guideline development not assessed, or unclear if funding body has influenced guideline development	

845 High quality review = score of $\ge 3/5$

846

847

Trials were deemed to have fulfilled criteria for importance if they were cited in the results of a high-quality CPG. The remaining uncited trials were assessed for inclusion in a point-of-care medical database article by two authors (NH & HM). Using disease and intervention keywords, we searched UpToDate¹¹ to identify any articles citing the

852 remaining trials.

853

Assessment of citation of trial results in Clinical Practice Guidelines (CPGs) was

repeated in October 2021 by NH & HM for those trials without an informative citation when first assessed.

eMethods 10 - Operationalization of modified Cochrane Risk of Bias score 858

859 860 We employed a modified 2011 version of the Cochrane Risk of Bias Assessment Tool 861 (detailed criteria for judging risk of bias provided in Table 8.5d of the Cochrane Handbook for Systematic Reviews of Interventions version 5.1)¹². When available, ROB 862 scores were extracted directly from high-quality SRs identified during the assessment 863 of trial importance. When not available, assessment was independently carried out by 864 two authors (NH & HM), with differences resolved by a third (JK). Assessment included 865 the following elements: i) random sequence generation; ii) allocation concealment; iii) 866 blinding of participants and personnel; iv) blinding of outcome assessment; v) 867 incomplete outcome data; and, vi) selective reporting. Trials were deemed of sufficient 868 design quality if all elements were deemed to be "low risk of bias" or if a minority of 869 elements were deemed of "unclear risk" and the remaining were "low risk." Any "high 870 risk" of bias element equated with poor trial design. 871

872

Of the 63 trials assessed for trial design, 36 ROB scores were extracted directly from 873

- 874 SRs, the remaining 27 trials were assessed by the study team.
- 875

876

878 eMethods 11 – Deviations to the Study Protocol

879

880 1. For our feasibility assessment, we first evaluated feasibility of goal patient enrollment 881 and planned date of primary completion based on the first record available on 882 ClinicalTrials.gov (this was independently double-coded). However, we repeated this assessment using the final registration record prior to trial start date as this was felt to 883 provide a better evaluation of feasibility, allowing investigators to adjust enrollment 884 plans and primary outcome timeline prior to trial start. The latter method was single 885 886 coded and did not produce any change in the results of our feasibility assessment. 887 2. We performed two additional sensitivity analyses on the primary outcome: i) 888 889 excluding all trials in the lower quartile of goal patient enrollment; and, ii) excluding all 890 phase 1/2 and phase 2 trials from the assessment. 891 892 3. We excluded evaluation of primary outcome integrity from our assessment of trial informativeness, given concerns that there can be scientifically valid reasons for 893 894 altering a primary outcome. For example, a primary outcome might be changed due to 895 evolving clinical practice or in response to new data from outside the trial. 896 897 4. We excluded trials of interventions that were subject to FDA regulations, but were 898 never approved for any indication, or were FDA approved after trial start, but did not have 5 years of follow-up time from 31 October 31 2016 post-approval to allow for 899 900 enough time for trial results to be included in systematic reviews/clinical practice quidelines/UpToDate. 901 902 903 5. We excluded Indeterminate trials from our cohort, defined as ongoing trials that have 904 not surpassed double the allotted time for primary outcome completion (as first stated in the historical clinicaltrials.gov registration record) 905 906

908 eMethods 12 – STROBE Checklist for Cohort Studies

	ltem No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed		5-6	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	Figure1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-11
Statistical methods	12	 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses 	10-11
Results			
Participants	13*	 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram 	Figure1 7
Descriptive data	14*	 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) 	Table1 11-12
Outcome data	15*	Report numbers of outcome events or summary measures over time	13

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates	13-
		and their precision (eg, 95% confidence interval). Make clear which confounders	14
		were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done – eg analyses of subgroups and interactions, and	13-
		sensitivity analyses	14
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or	19-
		imprecision. Discuss both direction and magnitude of any potential bias	20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,	17-
		multiplicity of analyses, results from similar studies, and other relevant evidence	20
Generalisability	21	Discuss the generalisability (external validity) of the study results	20
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2

913 eTable 2 – Inter-rater Agreement Rates

914

Category	Unweighted Cohen's Kappa
Screening trials for inclusion/exclusion	0.83
Evaluating trial Feasibility	0.98
Evaluating trial Reporting	0.79
Evaluating trial Importance	0.67
Evaluating trial Design	0.84

915

917 eTable 3 – Proportion of Trials Meeting Each Criterion for Informativeness

918

Condition for Informativeness	Ratio	% (95% CI)
Feasibility	90 of 125 trials	72.0 (63.3 – 79.7)
Reporting	81 of 90 trials	90.0 (81.9 – 95.3)
Importance	63 of 81 trials	77.8 (67.2 – 86.3)
Design	33 of 63 trials	52.4 (39.4 – 65.1)

919

921 eTable 4 – Phase 4 Trials Not Meeting All 4 Informativeness Criteria

NCT	Disease	Title	Trial Status	Sponsor	Informativeness Assessment
NCT00954707	IHD	A Prospective, Randomized, Multi- Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)	Unknown (Previously, Active, NR)	Industry	Not cited in review documents
NCT00977938	IHD	A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions	Completed	Non- Industry	Elevated Risk of Bias Score
NCT01050348	IHD	A Double Blinded Randomized Placebo Controlled Study: To Investigate the Role of Upstream High Dose Statin Treatment in Patients With ST Segment Elevation Myocardial Infarction	Completed	Non- Industry	Not Reported
NCT01069003	IHD	EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy Drug Regimen	Completed	Industry	Elevated Risk of Bias Score
NCT01106534	IHD	XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)	Completed	Industry	Poor Feasibility
NCT01178268	IHD	XIENCE V Everolimus Eluting Coronary Stent System China: Post-Approval Randomized Control Trial	Completed	Industry	Not cited in review documents
NCT01221272	IHD	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging	Completed	Industry	Poor Feasibility
NCT01230892	IHD	The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease	Completed	Non- Industry	Not cited in review documents

NCT01246011	IHD	Significance of Antibodies to	Terminated	Non-	Poor Feasibility
		Heparin/Platelet Factor 4 Complex in		Industry	-
		Vein Graft Patency and Potential Role of			
		Argatroban for Prevention of Vein Graft			
		Occlusion			
NCT01101867	DM	Prandial Insulin Dosing Using the	Completed	Non-	Not cited in
		Carbohydrate Counting Technique in		Industry	review
		Hospitalized Patients With Diabetes			documents
NCT01267448	DM	A Pilot Study of Outpatient Discharge	Unknown	Non-	Poor Feasibility
		Therapy With Saxagliptin + Metformin	(Previously,	Industry	
		XR or Sulphonylurea for Recently	Recruiting)		
		Diagnosed Type 2 Diabetes Presenting			
		With Severe Hyperglycemia			
NCT00978796	DM	Pilot Study Assessing Glucose Effects	Completed	Non-	Not cited in
		of Sitagliptin (Januvia) in Adult Patients		Industry	review
		With Type 1 Diabetes			documents
NCT00979628	DM	Basal Bolus Versus Basal Insulin	Completed	Non-	Elevated Risk of
		Regimen for the Treatment of		Industry	Bias Score
		Hospitalized Patients With Type 2			
		Diabetes Mellitus			
NCT01107717	DM	Durability of Early Initial Combination	Active, NR	Non-	Poor Feasibility
		Therapy With		Industry	
		Exenatide/Pioglitazone/Metformin vs			
		Conventional Therapy in New Onset			
		Type 2 Diabetes			
NCT00939250	DM	A Comprehensive Intervention for	Completed	Non-	Poor Feasibility
		Diabetes and Comorbid Depression in		Industry	
		Primary Care			
NCT00950677	DM	The Effect of the Glucagon Suppressors	Completed	Non-	Not Reported
		Pramlintide and Exenatide on		Industry	
		Postprandial Glucose Metabolism in			
		Children With Type 2 Diabetes Mellitus			
NCT01221090	DM	Employing Diabetes Self-Management	Completed	Non-	Elevated Risk of
		Models to Reduce Health Disparities in		Industry	Bias Score
		Texas			

923 IHD – Ischemic Heart Disease

924 DM – Diabetes Mellitus

925

927 eTable 5 – Trials Not Cited in Clinical Review Documents

NCT	Disease	Title	Phase	Trial Status	Sponsor	Published Results
NCT00924118	IHD	A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Prevention of Ischemia- Reperfusion Injury Associated with Acute Myocardial Infarction	2	Completed	Non- Industry	NO
NCT00954707	IHD	A Prospective, Randomized, Multi- Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER Sirolimus-eluting Coronary Stent	4	Unknown (Previously, Active, Not Recruiting)	Industry	NO
NCT01175018	IHD	Anakinra to Prevent Adverse Post- infarction Remodeling	2	Completed	Non- Industry	YES
NCT01178268	IHD	XIENCE V Everolimus Eluting Coronary Stent System China: Post-Approval Randomized Control Trial	4	Completed	Industry	NO
NCT01230892	IHD	The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease	4	Completed	Non- Industry	YES
NCT01101867	DM	Prandial Insulin Dosing Using the Carbohydrate Counting Technique in Hospitalized Patients With Diabetes	4	Completed	Non- Industry	YES
NCT01194245	DM	A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro- PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog) in Patients With Type 1 Diabetes	2	Completed	Industry	NO
NCT00916357	DM	Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM	2	Completed	Industry	YES
NCT00993824	DM	Use of Continuous Glucose Monitoring With Ambulatory	2/3	Completed	Non- Industry	YES

		Glucose Profile Analysis to				
		Demonstrate the Glycemic Effect of				
		Colesevelam HCI (Welchol) in				
		Patients With Type 2 Diabetes				
NCT00918138	DM	A 4-Week, Multicenter,	3	Completed	Industry	YES
		Randomized, Double-Blind, Phase				
		3b Trial to Evaluate the Efficacy of				
		Saxagliptin in Combination With Metformin XR 1500 mg Versus Up-				
		titrated Metformin XR to 2000 mg				
		in Subjects With Type 2 Diabetes				
		Who Have Inadequate Glycemic				
		Control With Diet and Exercise and				
		a Stable Dose of Metformin XR				
		1500 mg				
NCT00844090	DM	The Role of Apathy in Glycemic	NA	Completed	Non-	NO
107007070700	514	Control			Industry	
NCT00978796	DM	Pilot Study Assessing Glucose	4	Completed	Non-	YES
		Effects of Sitagliptin (Januvia) in Adult Patients With Type 1			Industry	
		Diabetes				
NCT01089569	DM	Evaluation of Insulin Glargine and	NA	Completed	Non-	YES
		Exenatide: A Randomized Clinical			Industry	
		Trial with Continuous Glucose				
		Monitoring and Ambulatory				
NOTOOLOOOO		Glucose Profile Analysis				
NCT00918203	Lung CA	A Randomized Phase 2 Study of	2	Completed	Industry	YES
	CA	Human Anti-PDGFRa Monoclonal Antibody (IMC-3G3) with				
		Paclitaxel/Carboplatin or				
		Paclitaxel/Carboplatin Alone in				
		Previously Untreated Patients with				
		Locally Advanced or Metastatic				
		Non-Small Cell Lung Cancer				
NCT00976677	Lung	Randomized Double-Blind Placebo	2	Terminated	Non-	NO
	CA	Controlled Phase II Trial Evaluating			Industry	
		Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and				
		Ineligible) Advanced Non-Small				
		Cell Lung Cancer				
NCT00977470	Lung	Phase II Study of Erlotinib With or	2	Active, NR	Non-	NO
	CA	Without Hydroxychloroquine in		-	Industry	
		Patients With Previously Untreated				
		Advanced NSCLC and EGFR				
	Luna	Mutations Phase III Randomized Trial of BIBW	3	Completed	المطرب ملاسم ا	VEO
NCT01085136	Lung CA	2992 Plus Weekly Paclitaxel Versus	3	Completed	Industry	YES
	07	Investigator's Choice of				
		Chemotherapy Following BIBW				
		2992 Monotherapy in Non-Small				
		Cell Lung Cancer Patients Failing				
		Previous Erlotinib or Gefitinib				
		Treatment (LUX Lung 5)				

NCT01104155	Lung CA	Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated,	2	Completed	Industry	YES
		Advanced Non-Small Cell Lung				
		Cancer				

929 IHD – Ischemic Heart Disease

930 DM – Diabetes Mellitus

931 Lung CA – Lung Cancer

932 933	Suppl	ementary Bibliography
934	1.	Drugs@FDA https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
935 936	2.	510(k) Premarket Notification https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm .
937 938	3.	Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical Trials. <i>JAMA</i> . 2019;322(9):813-814.
939 940	4.	Cochrane Database of Systematic Reviews. (https://www.cochranelibrary.com/cdsr/reviews)
941 942	5.	Agency for Healthcare Research and Quality. (https://effectivehealthcare.ahrq.gov).
943	6.	Scopus. (<u>https://www.scopus.com</u>)
944	7.	Google Scholar. (<u>https://scholar.google.ca</u>).
945 946 947	8.	Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. <i>J Clin Epidemiol.</i> 2009;62(10):1013-1020.
948 949 950 951	9.	Flodgren G, Eccles MP, Shepperd S, Scott A, Parmelli E, Beyer FR. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes. <i>Cochrane Database Syst Rev.</i> 2011(7):CD009255.
952 953 954	10.	Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. <i>CMAJ</i> . 2010;182(18):E839-842.
955	11.	UpToDate. (https://www.uptodate.com/home).
956 957 958 959 960 961	12.	The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. Eds J.P.T. Higgins & S.Green. 2011. https://training.cochrane.org/handbook/archive/v5.1/.